Group 1 - The core index, the CESHKB, increased by 2.7% to 7293.11 points with a trading volume of 11.568 billion [1] - The CESHKB has risen by 15.52% in the past month, 19.54% in the past three months, and 58.49% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB include: CanSino Biologics (10.91%), Innovent Biologics (9.99%), BeiGene (9.73%), WuXi Biologics (9.42%), 3SBio (8.11%), Zai Lab (6.05%), WuXi AppTec (5.56%), Kelun-Biotech (5.15%), Kingstar Bio (4.37%), and Ascentage Pharma-B (3.89%) [1] - The CESHKB is entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, specifically in pharmaceuticals and biotechnology, also at a 100% allocation [2]

Group 1: Market Overview - The Hang Seng Index (HSI) closed at 23,689, close to the middle line of the Bollinger Bands at 23,718, indicating a neutral technical signal with support at 23,105 and resistance at 24,000 [2] - Investors are divided, with some holding bullish certificates expecting a rebound above 23,800, while others are buying put options anticipating a drop to 19,000 [1] Group 2: Company Analysis - WuXi Biologics (02269.HK) is experiencing a rebound from a low of 23.1, but the overall trend remains bearish with a sell signal from 10 sell and 4 buy indicators, suggesting a cautious outlook with key levels at 21.9 and 20.6 [4] - China Construction Bank (00939.HK) has stabilized above 7.8, with investors speculating a challenge to the 8.0 mark [7] - SMIC (00981.HK) has shown a rebound for two consecutive days, with a buy signal from 12 buy and 3 sell indicators, needing to break resistance at 41.7 and 43.8 to reach 45 [8] - Li Auto-W (02015.HK) has fallen for 10 days, with a current sell signal from 9 sell and 6 buy indicators, indicating a weak trend with support at 101.5 [11] - Sunny Optical Technology (02382.HK) is fluctuating around 65, with a buy signal from 15 buy and 2 sell indicators, suggesting potential upward movement if it breaks resistance at 66.8 [14]

金融界2025年6月23日消息，中欧医疗创新股票A(006228) 最新净值1.3629元，增长2.04%。该基金近1个 月收益率6.36%，同类排名28|561；近6个月收益率28.48%，同类排名18|548；今年来收益率31.07%，同 类排名17|550。 中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年3月31日，中欧医疗创新股 票A规模46.75亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 ...

Market Performance - As of June 23, 2025, the Shanghai Composite Index rose by 0.65% to 3381.58 points, while the Shenzhen Component Index increased by 0.43% to 10048.39 points, and the ChiNext Index gained 0.39% to 2017.63 points. The total trading volume of both markets reached 1.12 trillion yuan, marking the 18th consecutive day of exceeding 1 trillion yuan in trading volume [1]. Industry Highlights - The ground weaponry sector showed strong performance, surging by 3.81%, followed by energy metals and animal health, which rose by 3.54% and 3.28%, respectively. A total of 986 non-currency ETFs increased, with an 85% rise ratio [2]. - The China Securities Financial Technology Theme Index increased by 4.34%, with the Financial Technology ETFs from Huaxia, Huabao, and Bosera rising by 4.64%, 4.49%, and 4.20%, respectively [2]. - The National Stock Exchange's Hong Kong Stock Connect Innovative Drug Index rose by 2.64%, with the corresponding ETFs increasing by 3.69%, 3.61%, and 3.50% [2]. - The China Securities Military Industry Index saw an increase of 1.66% [2]. ETF Performance - The Financial Technology ETF from Huaxia (516100.SH) recorded a rise of 4.64%, with a total share size of 233 million. It closely tracks the China Securities Financial Technology Theme Index, which includes major companies in the computer industry [3]. - The Innovation 50 ETF from ICBC (159370.SZ) increased by 3.87%, with a share size of 228 million. It tracks the Innovation 50 Index, reflecting the performance of the top 50 stocks in the ChiNext market [4]. - The Hong Kong Stock Connect Innovative Drug ETF from ICBC (159217.SZ) rose by 3.69%, with a total share size of 3.481 billion. It tracks the National Stock Connect Innovative Drug Index, which includes leading companies in the innovative drug sector [5]. Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the China Securities Financial Technology Theme Index is 74.22, which is lower than 88.86% of the time over the past three years [4]. - The Innovation 50 Index's PE-TTM stands at 29.61, below 44.12% of the time in the last three years [5]. - The National Stock Connect Innovative Drug Index has a PE-TTM of 31.37, lower than 20.79% of the time in the past three years [6]. Declining ETFs - A total of 145 non-currency ETFs declined, with a 12% drop ratio. The Dongzheng Stock Price Index and Nikkei 225 Index fell by 0.36% and 0.13%, respectively [6]. - The National Defense Military Industry ETF (512810.SH) experienced a significant drop of 49.21%, with a total share size of 1.024 billion [8].

Group 1 - The market sentiment around Hai Tian Wei Ye has been volatile, with initial enthusiasm leading to a significant drop in stock price on the listing day, falling below the issue price [1][2] - The recent trend in the market shows that the perception of risk-free arbitrage in IPOs has shifted, with a high probability of losses being observed in recent offerings [2][3] - The performance of other companies like Hengrui Medicine and CATL has created a misleading expectation of easy profits from IPOs, contributing to the current market dynamics [2][6] Group 2 - The recent market downturn has affected various sectors, including new consumption and innovative pharmaceuticals, indicating a broader sentiment shift [6] - The liquidity in the Hong Kong market remains high, as evidenced by the drop in overnight Hibor rates, yet this has not translated into positive market performance for many stocks [6] - The focus on stocks that are currently declining is emphasized, suggesting a strategy to concentrate on potential recovery opportunities rather than chasing new IPOs [4][6]

Investment Rating - The report maintains an optimistic outlook on the orthopedic consumables industry, indicating potential for growth and investment opportunities in the sector [9]. Core Viewpoints - The orthopedic consumables market is segmented into joint, spine, trauma, and sports medicine categories, with joint and spine products holding significant market shares [16][12]. - The report highlights the increasing domestic replacement rate driven by centralized procurement policies, which is expected to enhance the competitiveness of local manufacturers [22][24]. - The orthopedic consumables market is projected to grow significantly, with joint products expected to reach a market size of 408 billion yuan by 2029, reflecting a CAGR of 16.9% [21]. - The report emphasizes the rapid development of the sports medicine segment, with a projected CAGR of 28.7%, indicating a growing market opportunity [21]. Market Overview - The orthopedic consumables market in China is expected to reach 592 billion yuan by 2024, representing 17% of the global orthopedic consumables market, which is projected to be 48.6 billion USD [38]. - The report outlines the increasing trend of domestic companies expanding their operations overseas, with significant growth in the proportion of revenue from international markets for companies like Spring Medical and Dabo Medical [39][40]. Segment Analysis - **Joint Products**: The market size for joint products is expected to grow from 187 billion yuan in 2024 to 408 billion yuan by 2029, driven by advancements in surgical techniques and technology [21]. - **Spine Products**: The spine product market is projected to grow from 171 billion yuan in 2024 to 335 billion yuan by 2029, supported by demographic trends such as aging populations [21]. - **Trauma Products**: The trauma segment is expected to maintain steady growth, with a market size projected to reach 315 billion yuan by 2029 [21]. - **Sports Medicine**: The sports medicine market is anticipated to grow rapidly, from 41 billion yuan in 2022 to 145 billion yuan by 2027 [21]. Procurement Progress - The report details the progress of centralized procurement in the orthopedic sector, noting significant price reductions and increased participation from domestic manufacturers [25][29][36]. - The first round of national procurement for joint products resulted in an average price drop of 82%, with a follow-up procurement cycle expected to maintain moderate price reductions [26][31]. - The spine product procurement saw an average price reduction of 84%, with a high participation rate from manufacturers [31]. Domestic Replacement Rate - The report indicates a significant increase in the domestic replacement rate for orthopedic consumables, with joint products' domestic rate rising from 47% in 2020 to an expected 79% by 2024 [24]. - The spine and trauma segments are also experiencing similar trends, with domestic replacement rates projected to reach 80% and 91%, respectively, by 2024 [24].

Quantitative Models and Construction 1. Model Name: Hang Seng Hong Kong Innovative Drug Index (CNY) - **Model Construction Idea**: The index selects up to 50 listed companies in the Hong Kong market whose main business involves innovative drug research and development, reflecting the overall performance of innovative drug-themed listed companies in Hong Kong[37][61] - **Model Construction Process**: - **Sample Space**: Combines the sample space of the CSI Hong Kong 300 Index and the CSI Hong Kong Stock Connect Composite Index[38] - **Selection Criteria**: - Liquidity: Average daily turnover over the past year must not be less than HKD 10 million - Business Focus: Companies involved in innovative drug R&D or providing related services are selected - Market Cap: Top 50 securities by average daily market cap over the past year are included, or all securities if fewer than 50 meet the criteria - **Weighting Method**: Free-float market capitalization weighting, with individual stock weights capped at 10%[38] - **Adjustment Frequency**: Semi-annual adjustments in June and December[38] - **Model Evaluation**: The index focuses on mid-to-large innovative drug enterprises, with a high degree of industry purity, as 100% of its constituents belong to the "Pharmaceuticals and Biotechnology" secondary industry[43][44] --- Model Backtesting Results 1. Hang Seng Hong Kong Innovative Drug Index - **Annualized Return**: 8.54% (2019.1.1 - 2025.5.31)[49][50] - **Annualized Sharpe Ratio (IR)**: 0.41[49][50] - **Annualized Volatility**: 35.93%[49][50] - **Maximum Drawdown**: -68.18%[49][50]

Group 1 - The core viewpoint of the news is that the China Europe Medical Innovation Stock A (006228) has experienced a decline of 2.62% on June 19, with a cumulative drop of 9.02% over the last five trading days, indicating a downward trend in its performance [1] - As of the end of 2024, the fund has a total size of 4.675 billion yuan and has achieved a cumulative return of 33.78% since its establishment in February 2019 [1] - The holder structure shows that institutional investors hold 0.23 million shares, accounting for 0.61% of the total shares, while individual investors hold 38.37 million shares, making up 99.39% of the total [1] Group 2 - The current fund manager, Ms. Ge Lan, has a Ph.D. in Biomedical Engineering from Northwestern University and has extensive experience in the investment management field, having joined China Europe Fund Management in October 2014 [2] - Ms. Ge has managed several funds, including the China Europe Medical Health Mixed Securities Investment Fund since September 29, 2016, and has held various managerial positions in other funds [2] Group 3 - As of March 31, 2025, the top ten holdings of China Europe Medical Innovation Stock A account for a total of 75.62%, with the largest positions being WuXi AppTec (10.35%), Kelun-Biotech (10.15%), WuXi Biologics (9.82%), and WuXi AppTec (9.60%) [3]

Core Points - The Hong Kong Biotechnology Index (CESHKB) experienced a decline of 3.05%, closing at 7087.18 points with a trading volume of 11.816 billion [1] - Over the past month, the index has increased by 26.57%, by 25.92% over the last three months, and has risen 63.14% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Index Composition - The top ten weighted stocks in the index include: - CanSino Biologics (10.86%) - Innovent Biologics (10.22%) - WuXi Biologics (9.54%) - BeiGene (9.36%) - 3SBio (7.95%) - Zai Lab (6.01%) - WuXi AppTec (5.63%) - Kelun-Biotech (5.20%) - Genscript Biotech (4.44%) - Ascentage Pharma-B (3.91%) [1] Market and Industry Overview - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% representation in the pharmaceutical and healthcare sector [2]

Core Insights - The report highlights the cautious sentiment in the Hong Kong stock market, with the Hang Seng Index declining by 1.12% and significant trading volumes indicating a risk-averse environment [2][3] - The report discusses the performance of various sectors, noting that property stocks and Chinese brokerage firms experienced notable declines, while some consumer stocks showed resilience [4][5] Company Overview - The specific company under review is Xiangjiang Electric (2619.HK), a manufacturer of home electrical appliances, focusing on both electrical and non-electrical home products, primarily operating through ODM/OEM models [10] - The company’s revenue for 2022, 2023, and 2024 is projected to be 1.1 billion, 1.19 billion, and 1.5 billion CNY respectively, with year-on-year growth rates of 8.3% and 26.4% [11] Industry Status and Outlook - The global small appliance market is expected to grow from USD 156.4 billion in 2020 to USD 183.5 billion in 2024, with a CAGR of 4.1%, driven by increased demand during the pandemic [12] - China's small appliance exports are projected to rise from USD 58.4 billion in 2025 to USD 65.6 billion in 2029, with a CAGR of 2.9% [12] Competitive Landscape - The top ten companies in the Chinese kitchen small appliance market hold a combined market share of 36.9%, indicating a relatively low industry concentration, with the company ranked tenth at 0.8% market share [12] Challenges and Risks - The small appliance industry faces uncertainties due to fluctuating prices of key raw materials such as copper and aluminum, which have seen significant price increases from 2020 to 2024 [13] - The company relies heavily on a few major clients, with the top five clients accounting for 77.9% of revenue, indicating a high concentration risk [15] Strategic Advantages - The company has established stable partnerships with well-known global brands for over nine years, ensuring strong customer loyalty and stable order flow [14] IPO Details - The IPO subscription period is from June 17 to June 20, 2025, with trading expected to commence on June 25, 2025 [16] - The company aims to raise approximately HKD 172 million to HKD 202 million, with funds allocated for establishing a factory in Thailand and upgrading automation and digital capabilities [18] Investment Considerations - The expected IPO price range is HKD 2.86 to HKD 3.35, with a projected market capitalization of HKD 780 million to HKD 914 million post-IPO [19] - The company is in a net cash position with a projected net cash of 151 million CNY in 2024, although it faces uncertainties related to tariffs as an export-oriented business [19]